What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “QLS31905 will be administered every 3 weeks Intravenous infusion on day 1 of each cycle.”In the company’s words, NCT07716449 on ClinicalTrials.gov
- Tested for
- Gastric or Gastroesophageal Junction Adenocarcinoma, Pancreatic Cancer, Advanced Solid Tumor, CLDN18.2-positive Advanced Biliary Tract Cancer, Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma
- Main trialPhase 3
- “This study is a randomized, open, multicenter phase III clinical study designed to compare the efficacy and safety of QLS31905 injection combined with CAPOX versus sintilimab combined with CAPOX in the first-line treatment of CLDN18.2 positive, PD-L1 CPS \< 5 , Her-2 Negtive unresectable locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma.”In the company’s words, NCT07716449 on ClinicalTrials.gov
Other drugs for Gastric or Gastroesophageal Junction Adenocarcinoma
- PembrolizumabMerck & Co. · Phase 3
- CemiplimabRegeneron · Phase 3
- DarovasertibIDEAYA Biosciences · Phase 3
- FianlimabRegeneron · Phase 3
- BCD-217Biocad · Phase 3
- ISCIB1+Scancell Ltd · Phase 3
Coming up3
- DecPhase 2 trial completes · ClinicalTrials.gov
- Sep 2028Phase 3 trial completes · ClinicalTrials.gov
- Dec 2028Phase 3 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials7
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 3Recruiting | Sep 2028 | QLS31905 in Combination With CAPOX Versus Sintilimab in Combination With CAPOX as First-line Treatment in Patients With GC/GEJ | |
| Phase 3Recruiting | Dec 2028 | A Study to Compare QLS31905 and Chemotherapy With Placebo and Chemotherapy in Participants With Pancreatic Cancer | |
| Phase 2Not yet recruiting | 30 Jun 2026 | Study of QLS31905 and/or QL1706 Combination With Chemotherapy in the Advanced Malignant Solid Tumors | |
| Phase 2Not yet recruiting | Oct 2026 | Combination of QLS31905 and Chemotherapy ± QL2107 in Patients With CLDN18.2-positive Advanced Biliary Tract Cancer | |
| Phase 2Not yet recruiting | Dec 2026 | Combination of QLS31905, QL2107 and Chemotherapy as First-line Therapy in CLDN18.2-positive Unresectable Locally Advanced or Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma | |
| Phase 1/2Unknown | Oct 2024 | A Study of QLS31905 Combination Chemotherapy as First-Line Treatment in Patients With Advanced Solid Tumors | |
| Phase 1Unknown | 31 Dec 2022 | A Study of QLS31905 in Patients With Advanced Solid Tumors |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026